MTN-003D Stage 2 IDI Visit Procedures

Miriam Hartmann, MPH
Women's Global Health Imperative
RTI International
San Francisco, CA, USA



IDI Visit Checklist

Stage 2 IDI Visit Checklist

MTN-0	03D PTID:	Visit Date:
man h	Decembers	
Initials	Procedures	Processing .
		Preparation
		ower supply, extra butteries, etc.)
		stationery for note-taking, consent form, discussion guide,
	refreshments (if applicable)	
		status (PK results, HIV status, and study product group) Arrival, IC & Data Collection
	Greet participant and offer	
	Confirm participant identity	
		ament informed consent process per site SOPs:
		wide written informed consent = CONTINUE, have
	participant sign ICF, co home.	elect signed form, and offer a copy for participant to take
	☐ NOT willing and able to	o provide written informed consent => STOP, provide
	participant reimbursem	ent and thank her for her time. Document in PSF and
	participant file notes.	
	Confirm eligibility criteria	110000
	☐ ELIGIBLE = CONTIN	NUE.
	☐ NOTELIGIBLE = ST	OP. Document in Participant Status Form (PSF) and
	participant file notes.	
	Administer Demographic I	nformation Form (DEM)
	Review IDI ground rules:	in reason
	 No right or wrong 	
		then providing responses
	 Information shared 	i remains confidential
	 Cell phone off 	
	Conduct sections A-B of th	ne Stage 2 Discussion Guide
	Complete PK Response sec notes and second on PSF in	ction of PSF or note response to PK discussion in interview imediately following IDI.
	Conduct section C of the S card exercise.	tage 2 Discussion Guide, including completion of the them
	[For HIV positive participa	out] Conduct section D of the Stage 2 Discussion Guide.
	FGD Determination Is participant HIV negative non-adherence during this	, with "low drug detection" levels, and was open about IDI?
	□ Yes □ No	
	Is participant willing to joi	in an FGD with her peers?
	☐ No ☐ N/A [participant did no	t meet above criteria]

- Step-by-step guide to visit procedures
- Each line to be completed (or write "NA")

IDI Preparation

- Time confirmed with participant
- Appropriate space for interview identified and reserved
- Current versions of ICF, discussion guide, other tools (e.g. PK visuals, theme cards, etc.) and checklists
- Audio-recorder charged, has batteries, and tested that day for functionality
- Verify participant status (i.e. PK results, HIV status, study product group)

Outline of Visit Procedures

- Confirm identity
- Informed consent
- Confirm eligibility
- Demographic Information (DEM) form
- Begin IDI
- Fill out/note PK Response for/on Participant Status Form (PSF)
- Complete IDI
- Complete PSF

IDI Procedures: the Beginning

- Greet participant
- Confirm identity
 - How will this be done?
- Explain, conduct and document written informed consent
- Confirm eligibility criteria
 - What needs to be verified? How will this be done?

Demographic (DEM) Form

- No changes from Stage 1
- Interviewer-administered prior to IDI
- Available in English and local language
- 30 questions:
 - Some new information
 - Some verbatim to VOICE CRF data to record updates/ changes since VOICE data captured

DEM Form

CRF:

- Complete all header and footer items: PTID, date, initials and date
- Follow GCP in completing each question and making corrections (initial and date)
- Use blue or black ink
- Question guide on the reverse side

MTN-003D PTID					7	Visit Dat	e		
			d	d		MMM		уу	

MTN-(003D Demographic Information Form (DEM)	
type of	RVIEWER READS : The following are some basic question people participated in the discussion for this study. All the l not be shared with anyone else besides the research study	information you provide will be kept confidential
1.	What is your date of birth?	dd MMM yy If unknown, record age:
2.	How many children have you had who were alive at birth?	
3.	How many total children are you currently taking care of (i.e. children, grandchildren, etc.)?	
4.	What is your ethnic group or tribe? (mark ethnic group/tribe code)	Ethnic Tribe Code 99 Other, specify:
5.	What is the language most spoken at home? (mark language code)	Language Code Other, specify:
6.	Do you currently earn an income of your own?	$ \Box_1 \text{ Yes} \\ \Box_2 \text{ No } \Rightarrow \text{ If No, go to item 8} $
7.	How do you earn your current income? (mark all that apply)	☐ ₁ Formal employment ☐ ₂ Self-employment 8 ☐ ₃ Other, specify:

8.	What is your highest level of education? (mark one)	\square_1 No schooling
		☐ ₂ Primary school, not complete
		☐ ₃ Primary school, complete
		☐ ₄ Secondary school, not complete
		☐5 Secondary school, complete
		☐ ₆ Attended college or university
9.	What is your religion? (mark one)	\square_1 Christian
		\square_2 Muslim
		☐ ₃ Other specify:
		\square_4 None \rightarrow If None, go to item 11
10.	How many times a week do you attend religious	\square_1 More than once a week
	services? (mark one)	\square_2 Once a week
		\square_3 Less than once a week
		□ ₄ Never
11.	Name of area/location where you currently live:	
12.	For how long have you lived in this location/area? (mark one)	or
		months years
13.	Do you consider this your home?	\square_1 Yes
		\square_2 No, specify
14.	Do you, or does someone in your family, own the	\square_1 Yes
	household you are currently living in?	\square_2 No

15.	How many rooms are in the household you are currently living in?	
16.	Does your household have:? (read options and mark all that apply)	\square_1 Electricity \square_2 A radio \square_3 A television \square_4 A mobile telephone \square_5 A non-mobile telephone \square_6 A refrigerator
17.	What kind of toilet facility does your household have? (mark toilet facility code)	Toilet Facility Code Other, specify:
18.	What is the main source of drinking water for members of your household? (mark water source code)	Water Source Code Other, specify:
19.	Do you own a mobile phone?	\square_1 Yes \square_2 No
20.	Are you currently married?	$ \begin{array}{ccc} $
21.	Do you currently have a primary sex partner? By primary sex partner, I mean a person you have sex with on a regular basis or who you consider to be your main partner.	$\square_1 \text{ Yes}$ $\square_2 \text{ No } \rightarrow \text{ if No, go to 29}$
22.	Is your [husband/primary sex partner] the same partner you had when you exited VOICE?	\square_1 Yes \square_2 No 10

23.	For how long have you had this partner? (mark one)	months years
24.	How old is your [husband/primary sex partner]?	□□□ □ ₉₉ Don't Know
25.	Are you currently living with your [husband/primary sex partner]?	\square_1 Yes \square_2 No
26.	Does he provide you with financial and/or material support?	\square_1 Yes \square_2 No
27.	Does he have any sex partners other than you?	☐₁ Yes ☐₂ No ☐₃ Don't Know
28.	In the past 3 months , have you had vaginal sex with your primary sex partner? By vaginal sex we mean when a man puts his penis inside of your vagina.	\square_1 Yes \square_2 No
29.	In the past 3 months , with how many other male partners have you had vaginal sex? By other male partners, we mean any man who is not your primary sex partner.	
30.	In total, how many different people have you had vaginal sex with in your lifetime ?	

IDI Procedures: the Middle

- Interview will follow guide
 - Primary research topics numbered and appear in gray
 - Primary research questions in bold
 - Probes bulleted
- Notes to be taken on separate sheets of paper
 - Separate sheets must be labeled with PTID, date and staff initials

IDI Procedures: the Middle

- The guide is a <u>guide</u>, not a script.
 Interview should flow naturally and flexibly
 - Acceptable to jump around
 - Acceptable to probe on spontaneous, relevant issues
 - Acceptable to rephrase probes
- □ However...
 - Ensure primary research topics/questions are addressed

Conduct Sections A-B

Section A. Use the following talking points as a guide for IDI participants and during both the individual consent period and the group discussion for FGD participants.

Impression of the VOICE Results

(For women from Stage 1: emphasize that we are still trying to understand VOICE, and that at the time when she was interviewed previously we did not have blood test results).

English: We would like to understand why so many women in VOICE did not take their products consistently so we can design products that women can take and improve future studies for HIV prevention. Since YOU are the expert, please help us by explaining your experience in VOICE.

Translation:

Additional Probes (Get feedback on the following specific points):

- Neither of the two tablets (<u>Truvada</u> or tenofovir) nor the gel were found to be effective in preventing HIV in VOICE
- When researchers looked at VOICE participants' blood tests they found that a majority of the women in VOICE (this means thousands of women) never had any drug from the study products in their blood.
- Because of these blood tests showing that women were not taking the products in VOICE, researchers could not determine if the products were protective against HIV.
- There are several other studies that were conducted more or less at the same time as VOICE, in Africa and other parts of the world that indicated that the products are protective against HIV, when they are taken consistently as directed.

Available tools: e.g. MTN press release, educational sheet for study results; local press clippings

Section B. Use the following talking points for IDI participants and during the individual consent period for FGD participants.

2. Participant's own PK results

Capture Reaction to PK Results

- Record on PSF or make a note of the participant's reaction
- If noted elsewhere during IDI, be familiar with response options on PSF

9.	Record your assessment of the	☐ ₁ Anger	☐1 Distress/Unhappiness
	participant's physical/emotional reaction	□ 1 Fear	☐1 Happiness
	upon hearing her PK results. (Select all	☐1 Sadness	☐ ₁ Surprise
	that apply)	☐1 Disbelief	1 Other, specify:

Conduct Section C

Section C. Use the following talking points for IDI participants and FGD participants in the group discussion setting.

3. Factors influencing adherence (spontaneously derived)

(Note the importance of eliciting all the reasons the participant spontaneously mentions as influencing adherence before probing on specific topics)

English:

- [For women with low drug detection:] What are all the reasons you were not able to take your products?
- [For women with high/inconsistent drug detection:] the drug data show that you took the
 product [some of/ most of/ all of] the time prior to coming to the study visits... What are all
 the reasons you were able to [some of/ most of/ all of] the time, take your products?

Translation:

- [For women with low drug detection:]
- [For women with high/inconsistent drug detection:]
- 4. All other factors influencing adherence (probing topics)
- [For IDI participants]: Do key theme card exercise.
- [For FGDs]: Use cards to facilitate conversations....

Additional Probes:

[For women with low drug detection:]

- What was happening (that influenced you not taking product)?
- How did reasons for non-use change over time, or did the reasons stay the same?

[For women with high/inconsistent drug detection:]

- How much did the visit act as a reminder to take the products?
- What situations or circumstances made it easier or more difficult to take the product daily?
 What was happening (that influenced you taking product)?

Conduct Section D [HIV+ Women]

Section D. Use the following talking points for IDI participants who have seroconverted:

8. Experience of product use and seroconversion

English: If it's okay with you, I'd like to talk more about your HIV sero-status...What in your view may have contributed to you getting HIV?

Translation:

Additional Probes:

- Was there any particular time or event where you think you may have gotten HIV?
- Have you had any recent changes in personal life, behaviors or circumstances that may have contributed to your getting HIV?
- What was your experience with taking the study product, both good and bad?
- What do you think about your participation in VOICE now, with all that happened to you?

CLOSING: Thank the participant for her invaluable contribution to the research and ask her if she has any questions or comments.

17

IDI Procedures: the End

- [If participant is HIV negative, had "low drug detection" levels, and has been open about non-adherence] ask if she would be willing to join an FGD of her peers.
- Thank and reimburse participant

Social Harms Form

- Social harms related or unrelated to VOICE and/or MTN-003D may be mentioned during interview
- No changes to form or procedures from Stage 1
- Slides from Protocol Training on SHs available at:
 - http://www.mtnstopshiv.org/node/4639

Post-Interview Procedures

- Complete Participant Status Form (PSF)
- Interviewers and note-takers: check recording and expand notes, if necessary
- Review CRFs for completeness and clarity
- 4. Complete IDI Debrief Report template

PSFs for Enrolled IDI Participants

- Captures
 - MTN-003D PTID,
 - VOICE PTID,
 - Stage 1 and Stage 2 status,
 - Drug detection level and response to PK results,
 - Enrollment, interview and termination dates
 - Reason for termination
- Will differ for potential FGD sparks

Ex. 1: IDI Ppt Only

MTN-003D PTID		Date Form Initiated	
3214	20	SEP	13
	dd	MMM	YY

MT	N-003D Stage 2 Participant Status Form (PS	F)		
Instr	uctions: This form is to be completed for any MTN	N-003D participant who is considered for S	Stage 2 pai	rticipation
1.	Complete VOICE PTID 3 2 1-7	8910-5		
			Yes	No
2.	Was the participant enrolled in MTN-003D the same as Stage 1)	Stage 1? (If yes, PTID will remain	Ø,	2
3.	Was the participant enrolled in MTN-003D	Stage 2?	M.	□2 GO TO 12
4.	Date of enrollment in MTN-003D Stage 2:	dd MMM yy		
5.	Date MTN-003D Stage 2 IDI conducted (record date or check N/A):	20 SEP 13 or dd MMM yy	N/A	
6.	Date MTN-003D Stage 2 FGD conducted (record date or check N/A):	dd MMM yy	N/A → _G	0.703
7.	FGD Participant Pseudonym:			
8.	What is the participant's drug detection level classification (mark one)?	☐₁ Low drug ☐₂ Inconsistent drug ☐₃ High drug		

9.	Record your assessment of the participant's physical/emotional reaction upon hearing her PK results. (Select all that apply)	☐ Anger ☐ Distress/ Unhappiness ☐ Fear ☐ Happiness ☐ Sadness ☐ Surprise ☐ Disbelief ☐ Other, specify:
10,	Date of termination from MTN-003D Stage 2:	20 SEP 13 dd MMM yy
11.	Reason for termination from MTN-003D Stage 2 (mark one):	☐2 Participant completed study ☐2 Inappropriate enrollment ☐3 Other, specify: →END FORM
12.	Reason for non-enrollment in MTN-003D Stage 2 (mark one):	☐ Did not give permission to be contacted ☐ Contacted, but refused participation, specify: ☐ Scheduled three times, did not show ☐ Eligibility criteria not met, specify: ☐ Did not provide written informed consent ☐ Other, specify:
Comn	nents:	

Ex. 2: IDI Ppt [Potential FGD Spark]

MTN-003D PTID		Date Form Initiated	
1234	18	SEP	13
	dd	MMM	yy

MTN	N-003D Stage 2 Participant Status Form (PS	F)		
Instr	uctions: This form is to be completed for any MTN	V-003D participant who is considered for	Stage 2 par	ticipation.
1.	Complete VOICE PTID 1 2 3 - 4	5678-9		
			Yes	No
2.	Was the participant enrolled in MTN-003D the same as Stage 1)	Stage 1? (If yes, PTID will remain	⊠ ₁	\square_2
3.	Was the participant enrolled in MTN-003D	Stage 2?	N.	☐2 GO TO 12
4,	Date of enrollment in MTN-003D Stage 2:	18 SEP 13 dd MMM yy		
5.	Date MTN-003D Stage 2 IDI conducted (record date or check N/A):	18 SEP 13 or dd MMM yy	N/A	
6.	Date MTN-003D Stage 2 FGD conducted (record date or check N/A):	dd MMM yy or	N/A → _{G0}	тов
7.	FGD Participant Pseudonym:			
8.	What is the participant's drug detection level classification (mark one)?	Low drug		

		The state of the s
9.	Record your assessment of the participant's physical/emotional reaction upon hearing her PK results. (Select all that apply)	☐ Anger ☐ Distress/ Unhappiness ☐ Fear ☐ Happiness ☐ Sadness ☐ Surprise ☐ Disbelief ☐ Other, specify:
10.	Date of termination from MTN-003D Stage 2:	dd MMM yy
11.	Reason for termination from MTN-003D Stage 2 (mark one):	☐ Participant completed study ☐ Inappropriate enrollment ☐ Other, specify: →END FORM
12.	Reason for non-enrollment in MTN-003D Stage 2 (mark one):	☐ Did not give permission to be contacted ☐ Contacted, but refused participation, specify: ☐ Scheduled three times, did not show ☐ Eligibility criteria not met, specify: ☐ Did not provide written informed consent ☐ Other, specify:
Comn	nents:	

PSFs for Those Not Enrolled

 A PSF should be completed for all those randomly preselected to be part of MTN-003D who are considered for enrollment

Ex. 1: Did Not Give PTC

MTN-0	003D PTID)					Form Ir			
9	9 9	d		\	9	3	E	P	1	
			_	dd			MMM	1	1	A

MT	N-003D Stage 2 Participant Status Form (PSF)			
Instr	ructions: This form is to be completed for any MTN-003D participant who is cons	sidered for .	Stage 2 par	rticipation.
1.	Complete VOICE PTID 202-35621-7			
			Yes	No
2.	Was the participant enrolled in MTN-003D Stage 1? (If yes, PTID will r the same as Stage 1)	remain		\boxtimes_2
3.	Was the participant enrolled in MTN-003D Stage 2?			Ø2 GO TO 12
4.	Date of enrollment in MTN-003D Stage 2: dd MMM y	у		
5.	Date MTN-003D Stage 2 IDI conducted (record date or check N/A): dd MMM yy	or	N/A	
6.	Date MTN-003D Stage 2 FGD conducted (record date or check N/A): dd MMM	or y	N/A → _G	отов
7.	FGD Participant Pseudonym:			

8.	What is the participant's drug detection level classification (mark one)?	☐₁ Low drug ☐₂ Inconsistent drug ☐₃ High drug		
9.	Record your assessment of the participant's physical/emotional reaction upon hearing her PK results. (Select all that apply)	☐₁ Anger ☐₁ Distress/ Unhappiness ☐₁ Fear ☐₁ Happiness ☐₁ Sadness ☐₁ Surprise ☐₁ Disbelief ☐₁ Other, specify:		
10.	Date of termination from MTN-003D Stage 2:	dd MMM yy		
11.	Reason for termination from MTN-003D Stage 2 (mark one):	☐ Participant completed study ☐ Inappropriate enrollment ☐ Other, specify: →END FORM		
12.	Reason for non-enrollment in MTN-003D Stage 2 (mark one):	☐ Did not give permission to be contacted ☐ Contacted, but refused participation, specify: ☐ Scheduled three times, did not show ☐ Eligibility criteria not met, specify: ☐ Did not provide written informed consent ☐ Other, specify:		
Comn	nents:			

Ex. 2: "No Show"

MTN-003D PTID	9999		Date Form Initiated	
4300	MAT 30/001/13	23	SEP	13
		dd	MMM	yy

MT	N-003D Stage 2 Participant Status Form (PSI	(7)		
Instri	uctions: This form is to be completed for any MTN	-003D participant who is considered for S	Stage 2 par	rticipation
1.	Complete VOICE PTID 414-6	2310-5		
	1		Yes	No
2.	Was the participant enrolled in MTN-003D : the same as Stage 1)	Stage 1? (If yes, PTID will remain		⊠2
3.	Was the participant enrolled in MTN-003D Stage 2?			GO TO 12
4.	Date of enrollment in MTN-003D Stage 2:	dd MMM yy		
5.	Date MTN-003D Stage 2 IDI conducted (record date or check N/A):	dd MMM yy	N/A	
6.	Date MTN-003D Stage 2 FGD conducted (record date or check N/A):	dd MMM yy	N/A → G	отов
7.	FGD Participant Pseudonym:			

9.	Record your assessment of the participant's physical/emotional reaction upon hearing her PK results. (Select all that apply)	□ Anger □ Distress/ Unhappiness □ Fear □ Happiness □ Sadness □ Surprise □ Disbelief □ Other, specify:
10.	Date of termination from MTN-003D Stage 2:	dd MMM yy
11.	Reason for termination from MTN-003D Stage 2 (mark one):	☐ Participant completed study ☐ Inappropriate enrollment ☐ Other, specify: →END FORM
12.	Reason for non-enrollment in MTN-003D Stage 2 (mark one):	☐ Did not give permission to be contacted ☐ Contacted, but refused participation, specify: ☐ Scheduled three times, did not show ☐ Eligibility criteria not met, specify: ☐ Did not provide written informed consent ☐ Other, specify: ☐ Other, specify: ☐ Other
Par For an	ticipant scheduled on : - 25/SEP/13, did not show d did not show. No respon	23/SEP/13 did not show. Reschedule N. Rescheduled again for 30/0CT/13

IDI Debrief Report

- Purpose: To provide a summary of the participant's attitudes towards the key themes, participant mood, unique comments, and any other important information in REAL TIME
- Will be discussed on study team calls and shared across sites.

MTN-003D Stage 2 IDI Debriefing Report

Instructions: This report is to be completed on the same day as the IDI, and forwarded to RTI within one week of IDI completion. This report should be sent via email as a Word document.

Basic IDI Information:			
PTID:	IDI Date:		
Study Arm:	Interviewer #1:		
Study Arm: Drug Level Classification:	Interviewer #2:		
Participated in Stage 1 [Y/N]:	Note-taker:		
CRS/CTU:	Person Completing Form:		
IDI Venue:			
n	skriefing Commons		

- How did the IDI go today? (Describe in detail your subjective impressions of how the participant behaved, their emotional reactions [excited, sad, laughed, bored, confused, disappointed etc.], and any other important information about the context and experience)
- How did the participant respond to the PK results discussion? (Record which visual representation was used to describe results to the participant, if any, as well as details about the participant's emotional/physical reaction that expand upon their reaction recorded on the PSF)
- What were the most important themes or ideas discussed? (Describe in detail the most important ideas discussed within each of the main topic areas and any important issues that were raised)
 - a. Impression of VOICE Results:
 - b. Factors Affecting Adherence (distinguish between factors spontaneously mentioned and those discussed upon probing; include issues discussed during the theme card exercise, however record card codes in item 3, below):
 - c. Motivation to Join/Stay in the Trial:

- d. Recommendations for Future Trials/Products:
- e. [For HIV+ participants] HIV Sero-conversion Experience:
- 4. Record the numeric card codes selected during the theme identification exercise:
 - a. New Themes (write out any new themes identified as relevant):
 - b. Relevant Cards (Record card codes or descriptions (for new themes, if applicable) in order from most relevant to least relevant, as determined by the participant):
 - c. Not Relevant (record codes):
 - d. Not Sure/Undecided (record codes):
- Were there any unexpected or unanticipated findings? (Record anything unexpected, unanticipated, or new that was learned from this IDI)

QUESTIONS?